AI Portfolio Summary
In 2025 Q4, Fairmount Funds Management LLC maintained a portfolio of 17 distinct positions. They heavily accumulated shares in VIRIDIAN THERAPEUTIC, increasing their position by 13.1%. Conversely, Fairmount Funds Management LLC completely exited their position in AXSOME THERAPEUTICS .
Total Positions
17
Quarter
2025 Q4
Top Holding
COGT (24.3%)
Top 10 Concentration
92.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-17 of 17
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 24.34% | 11.63% |
#1
1
Prev: #2
|
9.7 | no change | no change |
P
S
|
9,003,418 | $319,801,407 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
APGE
APOGEE THERAPEU...
|
Healthcare | 11.77% | 7.32% |
#2
2
Prev: #4
|
4.7 | no change | no change |
P
S
|
2,048,647 | $154,631,876 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SYRE
SPYRE THERAPEUT...
|
Healthcare | 10.02% | 6.06% |
#3
7
Prev: #10
|
4.0 | no change | no change |
P
S
|
4,018,101 | $131,632,989 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VRDN
VIRIDIAN THERAP...
|
Healthcare | 9.27% | 6.72% |
#4
2
Prev: #6
|
5.7 | 454,545 | 13.1% |
P
S
|
3,914,458 | $121,817,933 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ORKA
ORUKA THERAPEUT...
|
Healthcare | 8.55% | 6.41% |
#5
2
Prev: #7
|
3.4 | no change | no change |
P
S
|
3,705,262 | $112,306,491 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DNTH
DIANTHUS THERAP...
|
Healthcare | 6.70% | 11.71% |
#6
5
Prev: #1
|
2.8 | -1,170,000 | -35.4% |
P
S
|
2,137,191 | $88,073,641 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ZBIO
ZENAS BIOPHARMA...
|
Healthcare | 6.11% | 3.78% |
#7
6
Prev: #13
|
4.5 | 316,219 | 16.7% |
P
S
|
2,209,025 | $80,209,698 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NUVL
NUVALENT INC
|
Healthcare | 5.57% | 5.66% |
#8
3
Prev: #11
|
2.2 | no change | no change |
P
S
|
727,563 | $73,185,562 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
JBIO
JADE BIOSCIENCE...
|
Healthcare | 5.35% | 2.50% |
#9
5
Prev: #14
|
4.3 | 1,333,126 | 41.4% |
P
S
|
4,553,494 | $70,260,412 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ELVN
ENLIVEN THERAPE...
|
Healthcare | 4.35% | 6.84% |
#10
5
Prev: #5
|
1.7 | no change | no change |
P
S
|
3,711,444 | $57,156,238 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KNSA
KINIKSA PHARMAC...
|
Healthcare | 4.14% | 6.19% |
#11
3
Prev: #8
|
1.7 | -453,151 | -25.6% |
P
S
|
1,319,688 | $54,437,130 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
CRESCENT BIOPHA...
|
—
|
Unknown | 2.48% | 1.48% |
#12
4
Prev: #16
|
3.3 | 1,360,000 | 98.0% |
P
S
|
2,747,866 | $32,589,691 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
IKT
INHIBIKASE THER...
|
Healthcare | 1.35% | 0.89% |
#13
4
Prev: #17
|
2.7 | 2,500,000 | 40.8% |
P
S
|
8,625,000 | $17,681,250 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AXSM
AXSOME THERAPEU...
|
Healthcare | 0.00% | 8.91% |
Sold All 😨
(Was: #3) |
0.3 | -815,176 | -100.0% |
CLOSED
|
— | $— | 2020 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SRRK
SCHOLAR ROCK HL...
|
Healthcare | 0.00% | 6.11% |
Sold All 😨
(Was: #9) |
0.3 | -1,824,031 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABVX
ABIVAX SA
|
Healthcare | 0.00% | 5.45% |
Sold All 😨
(Was: #12) |
0.3 | -713,434 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ATXS
ASTRIA THERAPEU...
|
Healthcare | 0.00% | 2.33% |
Sold All 😨
(Was: #15) |
0.3 | -3,554,129 | -100.0% |
CLOSED
|
— | $— | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-17 of 17 holdings